Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Zelmac Dosing Instructions Among Remaining Issues In FDA Review

Executive Summary

FDA will have to decide between a high dose or titrated regimen for Novartis' irritable bowel syndrome therapy Zelmac following a review by the Gastrointestinal Drugs Advisory Committee.
Advertisement

Related Content

Novartis Zelnorm Approval: FDA Accepts Overseas History, Active Surveillance
Novartis Zelnorm Approval: FDA Accepts Overseas History, Active Surveillance
Novartis Zelmac Well Tolerated In Alternating IBS, Study Suggests
Novartis Zelmac Well Tolerated In Alternating IBS, Study Suggests
Latest Zelmac Trial Focuses On 12 Mg Dose In Women; Drug Is "Approvable"
Zelmac Cost Analysis Data Could Define Use - Committee Member
Glaxo's Lotronex Risk-Management Program Emphasizes Appropriate Use
Glaxo's Lotronex Risk-Management Program Emphasizes Appropriate Use
Zelmac Pooled Study Results May Not Be Reflective Of Efficacy - FDA
Zelmac Pooled Study Results May Not Be Reflective Of Efficacy - FDA
Advertisement
UsernamePublicRestriction

Register

PS036278

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel